||| Menü 
Startseite
Firmenveranstaltungen, Neuemissionen

10/11
09/11
08/11
07/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
03/10
Geschäftsberichte, Werbung, Earnings, Marketing, Verordnungen

10/11
09/11
03/09
04/09
05/09
06/09
08/09
09/09
10/09
11/09
12/09
01/10
02/10
Fusionen, Übernahmen

11/11
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09
09/09
10/09
11/09
Personal, Belegschaft, Meldungen zu Produkten

06/08
07/08
08/08
09/08
10/08
11/08
12/08
01/09
02/09
03/09
04/09
05/09
06/09
07/09
08/09

Datenschutz
Impressum
Bankleitzahlen - online.de


Novartis announces changes to the Executive Committee

Novartis International AG /
Novartis announces changes to the Executive Committee
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.

* Felix R. Ehrat, Group General Counsel, will retire on June 1, 2018

* Shannon Thyme Klinger appointed to Group General Counsel

* Robert Weltevreden appointed Head of Novartis Business Services

Basel, May 16, 2018 - Novartis announced today that Felix R. Ehrat, Group
General Counsel of Novartis, has decided to retire from the company. Shannon
Thyme Klinger, currently Chief Ethics, Risk and Compliance Officer, will be
appointed Group General Counsel, effective June 1, 2018.

Mr. Ehrat, who has been Group General Counsel and Member of the Executive
Committee of Novartis since 2011, has decided to retire from his position in the
context of discussions surrounding Novartis' former agreement with Essential
Consultants, owned by Michael Cohen.

Mr. Ehrat said: "Although the contract was legally in order, it was an error. As
a co-signatory with our former CEO, I take personal responsibility to bring the
public debate on this matter to an end."

The Board of Directors and the Executive Committee of Novartis have the greatest
respect for Mr. Ehrat's decision to step down. Jörg Reinhardt, Chairman of the
Board of Directors said: "I appreciate Felix's decision even as we regret his
departure. We thank him for his contributions to the company as General
Counsel."

Vas Narasimhan, CEO of Novartis said: "During his term as Group General Counsel,
Felix was instrumental in further developing the global Legal Department of
Novartis, and he played a key role in the Executive Committee with his proven
expertise. Furthermore, he was a dedicated representative of the company's
interests in important national organizations such as economiesuisse,
SwissHoldings and Avenir Suisse. The Novartis leadership owes him considerable
thanks for his many contributions and wishes him all the best in his future
endeavors."

Shannon Thyme Klinger is currently Chief Ethics, Risk and Compliance Officer.
She became Chief Ethics and Compliance Officer and Global Head of Litigation in
2016 and joined the Novartis Executive Committee earlier this year. Ms. Klinger
joined Novartis in 2011, as General Counsel, North America, Sandoz US. She was
then appointed Global Head Legal and General Counsel for Sandoz. Ms. Klinger
holds a JD with Honors from the University of North Carolina  at Chapel Hill.
Before joining Novartis, Ms. Klinger was a litigation partner at Mayer Brown LLP
and Alston & Bird LLP and was Senior Vice President and General Counsel for
Solvay Pharmaceuticals Inc.

Vas Narasimhan said: "Shannon has a proven track record as a strong thought
leader with a commitment to ethics and integrity. She is an experienced and
gifted lawyer who's already made tremendous contributions to the company. She
brings the combination of private practice and industry experience in Europe and
the US that we need, and I have no doubt that the company will benefit from her
judgment and expertise."

Natacha Theytaz, Global Head Internal Audit will lead the Ethics, Risk and
Compliance organization ad interim. Ms. Theytaz will join Novartis from Roche,
effective June 1, 2018 as already announced internally by Novartis in January
2018.

In addition, Novartis announced today that Robert Weltevreden, previously Head
of Business Services for Syngenta will be appointed as Head of Novartis Business
Services (NBS). He will report to Vas Narasimhan, CEO of Novartis and  become a
member of the Executive Committee of Novartis (ECN). He will join Novartis on
June 1, 2018 and will be based in Basel.

At Syngenta, Robert Weltevreden led a business services organization of a
similar scope to NBS; including areas such as finance operations, human
resources operations, information technology, real estate and facility and fleet
management, as well as business process, data and project management. Before
that he had roles leading Business Process Management and global Finance
Operations for Syngenta. He holds a Masters Degree in International Finance,
Economics and Business Administration from the Erasmus University in Rotterdam
and an MBA in Financial Management from the Vlerick School for Management,
Ghent, Belgium.

"Robert's deep understanding of business services coupled with his strong
financial and commercial acumen make him the right person to lead Novartis
Business Services (NBS) in the next stage of its evolution," said Vas
Narasimhan. "Over the coming years he will play a critical role in driving even
higher levels of productivity and process standardization across Novartis. I am
confident that under his leadership our NBS team will be able to unlock even
greater value for us to reinvest in innovation and our exciting product
pipeline."

Disclaimer
This press release contains forward-looking statements within the meaning of the
United States Private Securities Litigation Reform Act of 1995. Forward-looking
statements can generally be identified by words such as "will," "appointed,"
"effective," "commitment," "confident," "pipeline," or similar terms, or by
express or implied discussions regarding the potential impact of the
announcements regarding Mr. Ehrat and Ms. Klinger on the reputation of Novartis,
and on the Novartis Legal function and on the Ethics, Ris and Compliance
function; regarding the potential impact of the announcement regarding Mr.
Weltevreden on the Novartis Business Services organization, including potential
improvements in productivity or business processes, and the potential impact of
any such improvements on the Novartis business, or regarding the potential
future financial impact of such changes. You should not place undue reliance on
these statements. Such forward-looking statements are based on our current
beliefs and expectations regarding future events, and are subject to significant
known and unknown risks and uncertainties. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those set forth in the forward-looking
statements. There can be no guarantee that as to how these announcements will be
received by investors or the public. Nor can there be any guarantee that
Novartis will improve productivity or business processes. Neither can there be
any guarantee that any of these announcements will have any particular impact on
the Novartis business.  Nor can there be any guarantee that any such changes
will have a positive financial impact on Novartis.  In particular, our
expectations could be affected by, among other things, the difficulties inherent
in making large-scale change changes to sizeable organizations; the
uncertainties inherent in research and development, including clinical trial
results and additional analysis of existing clinical data; unknown potential
developments in the Essential Consultants/Michael Cohen matter and related
matters; uncertainties regarding actual or potential legal proceedings,
including, among others actual or potential government investigations;
regulatory actions or delays or government regulation generally; our ability to
obtain or maintain proprietary intellectual property protection; the particular
prescribing preferences of physicians and patients; global trends toward health
care cost containment, including government, payor and general public pricing
and reimbursement pressures; general economic and industry conditions, including
the effects of the persistently weak economic and financial environment in many
countries; safety, quality or manufacturing issues, and other risks and factors
referred to in Novartis AG's current Form 20-F on file with the US Securities
and Exchange Commission. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has
leading positions globally in each of these areas. In 2017, the Group achieved
net sales of USD 49.1 billion, while R&D throughout the Group amounted to
approximately USD 9.0 billion. Novartis Group companies employ approximately
124,000 full-time-equivalent associates. Novartis products are sold in
approximately 155 countries around the world. For more information, please visit
http://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at
http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-
library
For questions about the site or required registration, please contact
media.relations@novartis.com

# #

Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations@novartis.com

Paul Barrett Antonio Ligi
Novartis Global External Communications Novartis Global External
+41 61 324 5224 (direct) Communications
+41 79 797 8137 (mobile) +41 61 324 1374 (office)
paul.barrett@novartis.com +41 79 723 3681 (mobile)
antonio.ligi@novartis.com


Eric Althoff
Novartis Global External Communications
+41 61 324 7999 (office)
+41 79 593 4202 (mobile)
eric.althoff@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

Central   North America

Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448

Pierre-Michel Bringer +41 61 324 1065 Cory Twining +1 212 830 2417

Thomas Hungerbuehler +41 61 324 8425

Isabella Zinck +41 61 324 7188



Media release (PDF):
http://hugin.info/134323/R/2193062/849308.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novartis International AG via GlobeNewswire



 
 ||| Themen-Infos 
· Mehr zu dem Thema Allgemeine Nachrichten

Der meistgelesene Artikel zu dem Thema Allgemeine Nachrichten:
FDA expands age indication for Menveo®, first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1]

 ||| Artikel Bewertung 
durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht



Web site engine's code is Copyright © 2003 by PHP-Nuke. All Rights Reserved. PHP-Nuke is Free Software released under the GNU/GPL license.
Erstellung der Seite: 0.066 Sekunden